U.S. Markets open in 6 hrs 49 mins

Glancy Prongay & Murray LLP Continues Investigation on Behalf of Intercept Pharmaceuticals, Inc. Investors (ICPT)


Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ: ICPT) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Intercept investigation page on our website at www.glancylaw.com/case/intercept-pharmaceuticals-inc.

On September 12, 2017, Intercept issued a letter warning physicians against overdosing patients with Ocaliva, the Company’s treatment for primary biliary cholangitis (“PBC”). The Company advised physicians that the drug has been tied to liver injuries and death among patients suffering from PBC. Then on September 21, 2017, the Food and Drug Administration issued a Safety Announcement that the drug “is being incorrectly dosed in some patients…resulting in an increased risk of serious liver injury and death.” The FDA noted that “In the 13 months after Ocaliva was approved in May 2016, FDA received reports of serious liver injury or death associated with Ocaliva.”

On this news, Intercept’s share price fell $12.11 or 16.4% to close at $61.59 on September 22,2017.

If you purchased Intercept securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171012006489/en/